The store will not work correctly when cookies are disabled.
JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
6-{4-{4-[2-(4-Methoxyphenyl)phenyl]piperazin-1-yl}butoxy}-2-methyl-2H-benzo[b][1,4]oxazin-3(4H)-one ID: ALA4799274
PubChem CID: 162676611
Max Phase: Preclinical
Molecular Formula: C30H35N3O4
Molecular Weight: 501.63
Molecule Type: Unknown
Associated Items:
Names and Identifiers Canonical SMILES: COc1ccc(-c2ccccc2N2CCN(CCCCOc3ccc4c(c3)NC(=O)C(C)O4)CC2)cc1
Standard InChI: InChI=1S/C30H35N3O4/c1-22-30(34)31-27-21-25(13-14-29(27)37-22)36-20-6-5-15-32-16-18-33(19-17-32)28-8-4-3-7-26(28)23-9-11-24(35-2)12-10-23/h3-4,7-14,21-22H,5-6,15-20H2,1-2H3,(H,31,34)
Standard InChI Key: YWHVBZKUIRBJHI-UHFFFAOYSA-N
Molfile:
RDKit 2D
37 41 0 0 0 0 0 0 0 0999 V2000
28.2123 -1.6880 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
28.2112 -2.5075 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
28.9192 -2.9165 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
29.6289 -2.5071 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
29.6260 -1.6844 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
28.9174 -1.2791 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
28.9209 -3.7315 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
28.2115 -4.1393 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
28.2109 -4.9558 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
28.9191 -5.3654 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
29.6292 -4.9525 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
29.6263 -4.1375 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
28.9199 -6.1825 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
27.5031 -2.9156 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
26.7958 -2.5064 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
27.5025 -3.7328 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
26.7945 -4.1408 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
26.0871 -3.7316 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
25.3790 -4.1397 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
26.0877 -2.9145 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
24.6717 -3.7305 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
23.9636 -4.1386 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
23.2562 -3.7294 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
22.5482 -4.1374 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
21.8408 -3.7283 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
21.8438 -2.9114 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
21.1372 -2.5023 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
21.1373 -4.1372 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
20.4302 -3.7319 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
20.4310 -2.9112 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
19.7247 -2.5025 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
19.0130 -2.9098 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
19.0122 -3.7304 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
19.7230 -4.1437 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
18.3062 -2.4995 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
18.3036 -4.1376 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
28.2127 -6.5919 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1 2 2 0
2 3 1 0
3 4 2 0
4 5 1 0
5 6 2 0
6 1 1 0
7 8 2 0
8 9 1 0
9 10 2 0
10 11 1 0
11 12 2 0
12 7 1 0
3 7 1 0
10 13 1 0
2 14 1 0
14 15 1 0
14 16 1 0
16 17 1 0
15 20 1 0
17 18 1 0
18 19 1 0
18 20 1 0
19 21 1 0
21 22 1 0
22 23 1 0
23 24 1 0
24 25 1 0
25 26 2 0
26 27 1 0
27 30 2 0
29 28 2 0
28 25 1 0
29 30 1 0
29 34 1 0
30 31 1 0
31 32 1 0
32 33 1 0
33 34 1 0
32 35 1 0
33 36 2 0
13 37 1 0
M END Associated Targets(Human) Associated Targets(non-human) Molecule Features Natural Product: NoOral: NoChemical Probe: NoParenteral: NoMolecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: NoChirality: NoAvailability: NoProdrug: No
Drug Indications MESH ID MESH Heading EFO IDs EFO Terms Max Phase for Indication References
Mechanisms of Action Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References
Calculated Properties Molecular Weight: 501.63Molecular Weight (Monoisotopic): 501.2628AlogP: 5.06#Rotatable Bonds: 9Polar Surface Area: 63.27Molecular Species: BASEHBA: 6HBD: 1#RO5 Violations: 2HBA (Lipinski): 7HBD (Lipinski): 1#RO5 Violations (Lipinski): 2CX Acidic pKa: 11.34CX Basic pKa: 8.51CX LogP: 4.99CX LogD: 3.85Aromatic Rings: 3Heavy Atoms: 37QED Weighted: 0.41Np Likeness Score: -0.74
References 1. Lacivita E,Niso M,Stama ML,Arzuaga A,Altamura C,Costa L,Desaphy JF,Ragozzino ME,Ciranna L,Leopoldo M. (2020) Privileged scaffold-based design to identify a novel drug-like 5-HT receptor-preferring agonist to target Fragile X syndrome., 199 [PMID:32442850 ] [10.1016/j.ejmech.2020.112395 ]